Lung Cancer Diagnostics Market Analysis

The lung cancer diagnostics market size is predicted to be valued at around US$30.84 billion by 2030 and US$18.92 billion in 2023, with a CAGR of 7.23% from 2024 to 2030.

Cancer is a prevalent health issue affecting different parts of the body, and its global incidence is on the rise. Lung cancer is one of the deadliest forms of cancer. The increasing number of cases and severe outcomes make early detection crucial for improving survival rates, as with all types of cancer. Like other illnesses, cancer diagnosis relies on medical professionals identifying symptoms. Recognizable signs of lung cancer encompass breathlessness, coughing, wheezing, finger jaundice, chest pain, and swallowing difficulties. The demand for superior lung cancer diagnostics has improved due to the rising prevalence of the disease globally. Smoking accounts for 80% of lung cancer deaths, while individuals who have never smoked account for the remaining 20%. Early detection techniques, including imaging technology and biomarker testing, enhance patient outcomes. The global lung cancer diagnostics market is expanding rapidly as healthcare systems prioritize screening programs and access to diagnostic equipment, fueling an increase in coping with prevailing diseases.

Adopting multimodal diagnostic procedures is revolutionizing the global lung cancer diagnostics market. Clinicians integrate diverse imaging modalities like CT, PET, and MRI alongside molecular and genetic analyses for accuracy in prognosis and treatment planning, driving market growth. The demand for multimodal diagnostic solutions continues to push upward, shaping the landscape of lung cancer diagnostics worldwide.

According to pressroom.cancer.org, By 2024, lung cancer will be the most commonly diagnosed cancer worldwide, with 2.5 million cases and the leading cause of cancer-related deaths, with 1.8 million fatalities.

Rising prevalence of Lung Cancer Worldwide

·        As per the American Cancer Society's lung cancer estimates in the United States for 2024, there are about 234,580 new cases of lung cancer and about 125,070 deaths.

·        Lung cancer is the leading cause of cancer-related deaths in Canada, accounting for one in every four cancer deaths. It is projected that over 31,000 Canadians will receive a lung cancer diagnosis in 2023, resulting in the deaths of more than 20,000 Canadians.

·        According to a January 2024 study, lung cancer ranks as the third most common cancer in France, with 52,777 new cases reported.

·        In 2022, lung cancer was the leading cause of cancer deaths in Germany, with over 45,000 deaths. The age-standardized incidence rate for lung cancer in Germany in 2022 was 32.7 per 100,000 for women and 52.1 per 100,000 for men.

·        In February 2024, nearly 118,000 people in Italy were living with a lung cancer diagnosis, with 77,200 cases in men.

·        In 2022, Spain is estimated to have 30,948 new lung cancer diagnoses, or 65 cases per 100,000 people per year. This includes 22,316 cases in men, or 96 cases per 100,000 men per year, and 8,632 cases in women, or 36 cases per 100,000 women per year.

·        According to GlobalData epidemiologists, the number of diagnosed NSCLC cases in the United Kingdom is expected to increase from 44,000 in 2024 to about 50,000 in 2032. Cancer Research U.K. projects that the average number of new lung cancer cases in the U.K. will increase from 55,400 in 2023–2025 to 66,200 in 2038–2040.

·        In 2022, China had 1,060,600 new cases of lung cancer, which was the most common of the top five cancers in the country.

·        According to the Apollo Hospitals Health of the Nation 2024 Report, India is expected to have 15.7 lakh cancer cases by 2025, up from 13.9 lakh in 2020.

China Lung Cancer Diagnostic Market

China has seen an increased demand for lung cancer diagnostics due to a rise in cases and the geriatric population. In China, lung cancer has the highest incidence and death rate among all types of cancer. The year 2020 saw 820,000 new cases and 710,000 deaths related to lung cancer. Diagnostic imaging testing is the country's most commonly used screening test for lung cancer. Imaging techniques for cancer detection, such as CT scans, MRI, nuclear medicine scans, ultrasound, mammograms, X-rays, and other radiographic tests, are considered reliable.  In 2023, there was notable interest in the effectiveness of targeting KRAS G12C mutations commonly found in NSCLC using Kirsten rat sarcoma homolog (KRAS) G12C inhibitors.

 Lung Cancer Diagnostics Key Players Analysis

The global lung cancer diagnostics market comprises of leading companies like llumina, Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG., Sanofi S.A., Agilent Technologies, and bioMérieux.

Lung Cancer Diagnostics Company News

·        In October 2023, DELFI Diagnostics launched FirstLook Lung, a blood-based test that offers a convenient, accurate, and personalized way to detect lung cancer. The test has a 99.7% negative predictive value for detecting lung cancer through low-dose CT (LDCT).

·        In August 2023, LUNGevity Foundation launched its Early Lung Cancer Center to speed up the development and widespread adoption of early detection and treatment options for lung cancer patients.

·        In May 2022, DELFI Diagnostics enrolled the first participants in the CASCADE-LUNG study, a multi-center trial for early lung cancer detection. Up to 15,000 participants will be enrolled during low-dose CT lung cancer screening.

·        In January 2020, Amgen Inc. announced collaborations with Guardant Health, Inc. and QIAGEN N.V. to develop companion diagnostics (CDx) for investigational cancer treatment AMG 510, the first KRASG12C inhibitor to advance to the clinic for treating multiple tumor types. The focus will be CDx tests for non-small cell lung cancer (NSCLC).

Diagnosis Test Type – Market breakup in 5 viewpoints:

1.    Imaging Test

2.    Biopsy

3.    Sputum Cytology

4.    Molecular Test

5.    Others

Cancer Type – Market breakup in 2 viewpoints:

1.    Non- Small Cell Lung Cancer

2.    Small Cell Lung Cancer

End-User – Market breakup in 5 viewpoints:

1.    Hospital Associated Labs

2.    Independent Diagnostic Laboratories

3.    Diagnostic Imaging Centers

4.    Cancer Research Institutes

5.    Others

Country – Market breakup in 25 Countries:

1.    North America

1.1    United States

1.2    Canada

2.    Europe

2.1    France

2.2    Germany

2.3    Italy

2.4    Spain

2.5    United Kingdom

2.6    Belgium

2.7    Netherlands

2.8    Turkey

3.    Asia Pacific

3.1    China

3.2    Japan

3.3    India

3.4    South Korea

3.5    Thailand

3.6    Malaysia

3.7    Indonesia

3.8    Australia

3.9    New Zealand

4.    Latin America

4.1    Brazil

4.2    Mexico

4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia

5.2    UAE

5.3    South Africa

All the Key players have been covered from 3 Viewpoints:

•    Overview

•    Recent Development

•    Revenue Analysis

Company Analysis:

1.    llumina

2.    Abbott Laboratories

3.    Thermo Fisher Scientific, Inc.

4.    QIAGEN N.V.

5.    Roche Holding AG.

6.    Sanofi S.A.

7.    Agilent Technologies

8.    bioMérieux.